Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

• Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete Response (CR) rate improved to 50% for Year 2 from 28% for Year 1
• Mean number of surgeries patients needed to control their RRP continued to drop from 4.1 surgeries per year prior to receiving INO-3107 to 1.7 for Year 1 to 0.9 for Year 2
• Partial data into the third 12-month period (Year 3 – median follow up 2.8 years following initial treatment) continued the trend of improvement and a reduced number of surgeries

Excerpt from the Press Release:

PLYMOUTH MEETING, Pa., Aug. 11, 2025 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from a retrospective study investigating the long-term clinical and safety response of patients treated with INO-3107 were published online in The Laryngoscope under the title “DNA Immunotherapy (INO-3107) Results in Long-term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP).”  The data demonstrate that a majority of patients experienced continued improvement, as measured by the number of surgical procedures needed after treatment with INO-3107, beyond the initial 12-month study period of the previously published Phase 1/2 trial. 

“The most important takeaway from this data is that the majority of patients experienced a reduction in surgeries following initial treatment with INO-3107, and almost all of those patients maintained or improved their response 2 years after initial treatment,” said Dr. Aaron Friedman, Associate Professor of Clinical Otolaryngology, Head and Neck Surgery, University of Cincinnati Medical Center, and a principal investigator on the trial. “With this continued improvement in clinical effect, we believe INO-3107 has the potential to change the trajectory of a patient’s disease and set a new standard of care for the RRP community.”

“Understanding how much every single surgery matters to patients, it is compelling to see the vast majority of patients experienced significant benefit from treatment with INO-3107, resulting in a reduction in the number of surgeries required to control their disease — a benefit that continued and often improved over time,” said Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer. “

Click the button below to read the entire Press Release:

Continue Reading The Press Release